OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Esteva Discusses T-DM1 in HER2-Positive Breast Cancer

June 22nd 2015

Francisco J. Esteva, MD, PhD, professor, Department of Medicine, associate director, Clinical Investigation Perlmutter Cancer Center, director, Breast Medical Oncology Program, NYU Langone Medical Center, discusses the efficacy of T-DM1 in patients with HER2-positive breast cancer.

Dr. Gary Schwartz on the Survival Benefit of Eribulin In Sarcoma

June 19th 2015

Gary Schwartz, MD, a medical oncologist and chief of the Hematology and Oncology Division at Columbia University Medical Center, discusses a randomized phase III trial investigating eribulin (Halaven) versus dacarbazine in patients with leiomyosarcoma and adipocytic sarcomas.

Nagi Kumar on Green Tea Catechin Treatment for Prostate Cancer Prevention

June 18th 2015

Nagi B. Kumar, PhD, Professor/Director, Cancer Chemoprevention, Moffitt Cancer Center, discusses the potential of green tea catechins for the prevention of prostate cancer.

Dr. O'Regan Discusses Breast Cancer Index in HER2-Positive/HR-Positive Patients

June 17th 2015

Ruth O'Regan, MD, medical oncology, Breast Cancer Clinic, University of Wisconsin Carbone Cancer Center, faculty, University of Wisconsin School of Medicine and Public Health, evaluates the Breast Cancer Index in patients with HER2-positive, HR-positive breast cancer for risk of late recurrence and endocrine benefit.

Dr. Rafii Discusses Clinical Outcomes With Olaparib in Patients with Ovarian Cancer

June 16th 2015

Saeed Rafii, MD, PhD, MRCP, medical director, Sarah Cannon Research Institute, discusses factors that influence clinical outcomes to olaparib in patients with BRCA1/2-mutant ovarian cancer.

Dr. Khorana on Blood Clots in Patients with Cancer

June 15th 2015

Alok Khorana, MD, medical oncologist, Cleveland Clinic, discusses blood clot risk and treatment for patients with cancer.

Melinda Irwin on Impact of Exercise on Survivors' Quality of Life

June 15th 2015

Melinda Liggett Irwin, PhD, MPH, associate professor of epidemiology (chronic diseases), Yale School of Public Health, co-program leader, Cancer Prevention and Control Research Program, Yale Cancer Center, discusses the impact of the LIVESTRONG at the YMCA Program on survivors' fitness, physical activity, and quality of life.

Holli Dilks on Molecular Profiling

June 12th 2015

Holli Dilks, PhD, Director, Personalized Medicine Operations Sarah Cannon Research Institute, discusses molecular profiling.

Dr. Goldberg on PD-1 Blockade in Tumors with Mismatch Repair Deficiency

June 12th 2015

Richard Goldberg, MD, Ohio State University Comprehensive Cancer Center-James Cancer Hospital, discusses PD-1 blockade in tumors with mismatch repair deficiency.

Dr. Brahmer on Impact of CheckMate-057 in NSCLC

June 11th 2015

Julie R. Brahmer, MD, interim director, Sidney Kimmel Comprehensive Cancer Center, associate professor of oncology, Johns Hopkins Medicine, discusses how the CheckMate-057 trial could impact the treatment of non-small cell lung cancer (NSCLC).

Dr. Jurcic on Lintuzumab and Low-Dose Cytarabine for AML

June 11th 2015

Joseph Jurcic, MD, professor of Clinical Medicine, director of the Hematologic Malignancies Section of the Hematology/Oncology Division, Columbia University Medical Center, discusses a phase I trial of lintuzumab and low-dose cytarabine (LDAC) in older patients with untreated acute myeloid leukemia (AML).

Dr. Saad Usmani on Daratumumab Monotherapy for Multiple Myeloma

June 11th 2015

Saad Z. Usmani, MD, director, Clinical Research Hematologic Malignancies, director, Plasma Cell Disorders, Levine Cancer Institute/Carolinas Healthcare System, discusses daratumumab for patients with relapsed/refractory multiple myeloma.

Dr. Dalgleish on IMM-101 With Gemcitabine for Pancreatic Cancer

June 10th 2015

Angus Dalgleish, MD, FRCP, FRACP, FRCPath, FMedSci, professor, Department of Oncology, St. George's, University of London, discusses a study that examined the combination of an immunomodulator with gemcitabine in patients with pancreatic cancer.

Dr. Kari Wisinski on Palbociclib for Metastatic Breast Cancer

June 10th 2015

Kari Wisinski, MD, medical oncologist with University Of Wisconsin Health and the University of Wisconsin Carbone Cancer Center, discusses the use of palbociclib for patients with ER-positive and HER2-negative breast cancer.

Dr. Jerome Kim on Geriatric Assessment Tool for Older Patients With Cancer

June 9th 2015

Jerome G. Kim, MD, medical oncologist, hematologist, Kaiser Permanente, discusses the feasibility of an assessment tool for older adults with cancer using web-based platforms.

Stefani Spranger on Î²-Catenin Signaling and Overcoming Immunotherapy Resistance

June 8th 2015

Stefani Spranger, PhD, University Chicago Melanoma Intrinsic Î²-Catenin Committee, discusses the effect of melanoma intrinsic Î²-catenin signaling on immune exclusion and resistance to immunotherapies.

Dr. Mesa on Pacritinib for Myelofibrosis

June 8th 2015

Ruben A. Mesa, MD, deputy director, Mayo Clinic, discusses PERSIST-1, a phase III study which examined pacribitinib as a treatment of myelofibrosis.

Dr. Tap on Olaratumab/Doxorubicin Combination in Soft Tissue Sarcomas

June 5th 2015

William Tap, MD, Medical Oncologist, Chief, Sarcoma Medical Oncology Service Memorial Sloan Kettering Cancer Center discusses the benefits of a olaratumab and doxorubicin combination treatment for advanced soft tissue sarcomas.

Dr. Philip McCarthy on Lenalidomide Maintenance for Multiple Myeloma

June 5th 2015

Philip McCarthy, MD, Professor of Oncology, Director, Blood and Marrow Transplant Center, Department of Medicine Roswell Park Cancer Institute, discusses the impact of the CALGB 100104 study which looked at lenalidomide maintenance following single autologous stem cell transplant for multiple myeloma.

Dr. Dung Le on Biomarker for PD-1 Agents in CRC

June 5th 2015

Dung T. Lee, MD, assistant professor of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medicine, discusses a biomarker for PD-1 agents in colorectal cancer (CRC).